Table 1 Base line characteristics of all study patients (n = 84)
Parameter | Â |
|---|---|
Gender | Â |
 Male | 65 (77.3 %) |
 Female | 19 (22.6 %) |
Age (y) | Â |
 Median (Range) | 61 (33–75) |
Performance status | Â |
 0/1/2 | 41/38/0 |
 3/4/unknown | 1/0/4 |
Histology | Â |
 Small cell carcinoma | 19 (22.6 %) |
 Adenocarcinoma | 37 (44 %) |
 Large-cell carcinoma | 2 (2.4 %) |
 Squamous cell carcinoma | 13 (15.5 %) |
 Malignant pleural mesothelioma | 6 (7.1 %) |
 Thymic malignancy | 2 (2.4 %) |
 Others | 5 (6 %) |
Cisplatin | Â |
 Median dose (mg/m2/day) (range) | 80 (40–80) |
 Median cycle (range) | 4 (1–6) |
Anticancer drugs | Â |
 Vinorelbine | 26 (31 %) |
 Etoposide | 14 (16.7 %) |
 Docetaxel | 12 (14.3 %) |
 Pemetrexed | 11 (13.1 %) |
 Gemcitabine | 4 (4.8 %) |
 S-1 | 4 (4.8 %) |
 Irinotecan | 2 (2.4 %) |
 Others | 11 (13.1 %) |
Serum creatinine (mg/dl) | Â |
 Median (range) | 0.72 (0.50–0.99) |
eGFR (mL/min/1.73Â m2) | Â |
 Median (range) | 81.1 (59.2–113.0) |
Charlson Comorbidity Index | Â |
 Median (range) | 6 (2–10) |